Investors

Company Profile

Founded in November 2012, ObsEva is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive health and pregnancy. We believe our expertise has led to the development of new and innovative therapies that have the potential to improve patient outcomes in reproductive health.

Financial Reports

Q1 Report 2022

May 17, 2022

Investor presentations

Corporate Deck May 2022

Corporate Deck April 2022

HCW Presentation September 13, 2021

Canaccord Presentation August 12, 2021

Wedbush Presentation August 11, 2021

HCW Presentation March 9, 2021

SVB Leerink Presentation Feb 24, 2021

JPM Presentation Jan 14, 2021

1 2 3

Press Releases

ObsEva Announces European Commission Marketing Authorization for Yselty® (linzagolix), an Oral GnRH Antagonist, for the Treatment of Uterine Fibroids

press release

June 17, 2022

-Yselty® (linzagolix) is the first and only approved GnRH antagonist to provide flexible dosing options with and without hormonal add-back…

Read more

ObsEva Announces Corporate Updates

press release

May 27, 2022

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – May 27, 2022 –…

Read more

ObsEva Presents Clinical Data on Oral GnRH Antagonist Linzagolix at Multiple Congresses

press release

May 25, 2022

-Data featured in two oral presentations at the 8th Society of Endometriosis and Uterine Disorders Congress and a poster presentation…

Read more
1 2 3 76

General Meetings

ObsEva Annual General Meeting 2022

May 18, 2022

Read more

ObsEva Annual General Meeting 2021

May 28, 2021

Read more
1 2 3 4

Upcoming Events

Year End 2022 Financial Results week of 06 March 2023

Event


    Read more

    Q3 2022 Financial Results week of 07 November 2022

    Event


      Read more

      Q2 2022 Financial Results week of 01 August 2022

      Event


        Read more
         

        Contacts

        ObsEva Switzerland Office

        Chemin des Aulx,12

        1228, Plan-Les-Ouates, Geneva, Switzerland

        +41 (0)22 552 3840


        contact@obseva.ch

        Media

        Katja Bührer

        +1 (917)-969-3438

        katja.buhrer@obseva.com

        Investor relations


        .


        Katja Bührer

        +1 (917)-969-3438

        katja.buhrer@obseva.com

        Clinical studies




        clinicaltrials@obseva.ch

        HR Office

        Charlotte Cadoux


        charlotte.cadoux@obseva.ch

        CEO Office

        +41 (0)22 552 1550


        shauna.dillon@obseva.ch

         

        Sign up for news

         
         

          * Type:


          InvestorHCPNursePayerHospital PharmacistRetail PharmacistOther












          Read our privacy policy here.


           

          Are you sure you want to leave ObsEva.com?

          We’re sorry to see you go. Choose one of the following actions to stay on the site or leave.

          Continue to link

          Disclaimer

          Note that the following information contains information on investigational medicinal products. These products have not yet been approved for marketing by the European Medicines Agency or the U.S. Food and Drug Administration and are still under development. Further additional investigations may be needed in order for the marketing authorization to be granted, which grant may depend on a variety of factors and is not guaranteed. Click on “return” if you do not wish to receive such information. By clicking on “continue” you acknowledge that you wish to receive scientific information on our investigational products.

          Continue

          Disclaimer

          Note that the following information contains information on investigational medicinal products. These products have not yet been approved for marketing by the European Medicines Agency or the U.S. Food and Drug Administration and are still under development. Further additional investigations may be needed in order for the marketing authorization to be granted, which grant may depend on a variety of factors and is not guaranteed. Click on “return” if you do not wish to receive such information. By clicking on “continue” you acknowledge that you wish to receive scientific information on our investigational products.

          Continue